Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08 Mai 2024 - 7:43PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of May 2024
Commission File Number 001-38512
Oncolytics Biotech Inc.
(Translation of registrant's name into English)
Suite 804, 322 11th Avenue SW
Calgary, Alberta, Canada T2R 0C5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's “home country”), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
| | | | | | | | |
EXHIBIT
NUMBER | | DESCRIPTION |
| | | |
| 99.1 | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | | | | | | | |
| | | Oncolytics Biotech Inc. (Registrant) |
| | | | | |
| | | | | |
| | | By: | | /s/ Kirk Look |
| Date: May 8, 2024 | | | | Kirk Look
Chief Financial Officer |
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, CA and CALGARY, AB, May 8, 2024 -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference, which is taking place May 14-15, 2024 at the InterContinental New York Barclay in New York, NY. Additional details on the fireside chat can be found below.
Date: Wednesday, May 15, 2024
Time: 10:30 a.m. ET
Location: InterContinental New York Barclay Grand Ballroom I, 2nd Floor
Webcast Link: Available by clicking here
Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, contact your RBC representative or email jpatton@oncolytics.ca.
A live webcast of the Company’s presentation will also be available on the Investor Relations page of Oncolytics’ website (LINK) and will be archived until August 13, 2024.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
| | | | | |
Company Contact Jon Patton Director of IR & Communication jpatton@oncolytics.ca | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 tim@lifesciadvisors.com |
Oncolytics Biotech (NASDAQ:ONCY)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Oncolytics Biotech (NASDAQ:ONCY)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
